论文部分内容阅读
目的:探讨载脂蛋白E基因(apolipoprotein E,apoE)多态性与个体间华法林维持剂量差异的关系。方法:采用聚合酶链反应/变性高效液相色谱技术,检测249例已获得华法林维持剂量患者的apoE基因型;比较不同基因型患者华法林维持剂量的差异。结果:249例患者中,基因型ε2/ε2,ε2/ε3,ε2/ε4,ε3/ε3,ε3/ε4,ε4/ε4的频率分别为1.20%,15.66%,0.80%,72.29%,9.24%,0.80%,等位基因ε2,ε3,ε4的频率分别为9.44%,84.74%,5.82%。ε2组(ε2/ε2,ε2/ε3)患者的华法林维持剂量为(3.24±1.36)mg/d,略高于ε3(ε3/ε3)和ε4(ε4/ε4,ε3/ε4)组[(2.91±1.14)mg/d,(2.98±1.05)mg/d],但差异无统计学意义(F=1.848,P>0.05)。结论:ApoE基因多态性可能不是影响华法林个体间用量差异的主要遗传因素。
Objective: To investigate the relationship between apolipoprotein E (apoE) polymorphism and warfarin maintenance dose among individuals. Methods: Polymerase chain reaction / denaturing high performance liquid chromatography was used to detect the apoE genotype of 249 patients who received warfarin maintenance dose. Differences of warfarin maintenance dose among different genotypes were compared. Results: The frequencies of genotypes ε2 / ε2, ε2 / ε3, ε2 / ε4, ε3 / ε3, ε3 / ε4 and ε4 / ε4 were 1.20%, 15.66%, 0.80%, 72.29% and 9.24% , 0.80% respectively. The frequencies of alleles ε2, ε3 and ε4 were 9.44%, 84.74% and 5.82% respectively. The warfarin maintenance dose was (3.24 ± 1.36) mg / d in patients with ε2 (ε2 / ε2, ε2 / ε3) slightly higher than that of ε3 (ε3 / ε3) and ε4 (ε4 / ε4, ε3 / ε4) (2.91 ± 1.14) mg / d, (2.98 ± 1.05) mg / d], but the difference was not statistically significant (F = 1.848, P> 0.05). CONCLUSION: ApoE gene polymorphism may not be the major genetic factor influencing the dosage difference among warfarin individuals.